Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis.

Authors

null

K. E. Bickel

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

K. E. Bickel , J. C. Niland , R. Mamet , C. C. Zornosa , D. S. Ettinger , K. Pisters , G. A. Otterson , M. Koczywas , M. E. Reid , M. S. Rabin , T. A. D'Amico , C. Earle , T. M. Pini , G. P. Kalemkerian

Organizations

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, City of Hope, Duarte, CA, National Comprehensive Cancer Network, Fort Washington, PA, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, M. D. Anderson Cancer Center, Houston, TX, The Ohio State University Medical Center and Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, OH, Roswell Park Cancer Institute, Buffalo, NY, Dana-Farber Cancer Institute, Boston, MA, Duke University Medical Center, Durham, NC, Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, University of Michigan, Ann Arbor, MI

Research Funding

No funding sources reported

Background: Aggressive EOL cancer care is a health care quality and cost issue. As lung cancer is the leading cause of cancer-related death in the U.S., and NCCN member institutions are considered to offer high-quality, evidence-based care, we examined the aggressiveness of mNSCLC EOL care at NCCN institutions. Methods: The NCCN database was queried to identify all deceased mNSCLC patients (pts) actively treated at 8 NCCN institutions from January 2007-June 2010. Aggressive EOL care was defined as 1) Starting a new CT regimen within 30 days of death (30d New), 2) Receipt of CT within 14 days of death (14d Any), or 3) Any ICU admission within the last 30 days of life (30d ICU). Among pts receiving CT, multivariate logistic regression was used to investigate associations between pt factors and aggressive CT use, controlling for age, NCCN institution, performance status (PS), and comorbidity. Multivariate analysis was not possible for the ICU model due to small sample size. Results: Among 1,092 eligible pts, 18.9% had 1 or more aggressive EOL events: 10.7% 30d New, 11.8% 14d Any, and 3.2% 30d ICU. Forty (34%) of 30d New pts started first line CT. Median age overall was 63 (range 25-91) and was 61 for all pts in the aggressive CT analyses. Initial overall PS was 57% 0-1 and was still predominantly 0-1 (23-38%) at the last CT in all groups. The multivariate results are listed below; an odds ratio > 1 indicating aggressive care more likely. Conclusions: While typical pt factors, such as age and PS, are used to determine fitness for CT receipt in mNSCLC, our analysis suggests that aggressive EOL CT receipt in mNSCLC at NCCN institutions is associated with other pt or clinical factors.


Analysis Pt factor Odds ratio 95% CI

30 d New*

Liver metastasis

1.82 1.19-2.77
Hospice discussion 2.73 1.24-6.04
14 d Any* Prior radiation 1.80 1.17-2.79
≥2 prior CT regimens 1.79 1.08-2.94
Prior smoker 0.42 0.24-0.73
Current smoker 0.51 0.28-0.94

*No associations seen with other factors, including age, institution, PS, comorbidity, other metastatic sites, clinical trial participation, time from metastatic diagnosis, gender, race, insurance type, histology, or smoking status at diagnosis.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer - Metastatic/Non-small Cell

Track

Lung Cancer

Sub Track

Metastatic

Citation

J Clin Oncol 29: 2011 (suppl; abstr 7537)

Abstract #

7537

Poster Bd #

32A

Abstract Disclosures